4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $12.20, for a total value of $19,947.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at $105,127.40. The trade was a 15.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Scott Bizily also recently made the following trade(s):

• On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $19,620.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Trading Up 19.4%

Shares of FDMT opened at $14.55 on Tuesday. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 12-month low of $5.97 and a 12-month high of $15.03. The firm has a market capitalization of $760.67 million, a PE ratio of -5.53 and a beta of 2.73. The stock’s fifty day simple moving average is $11.06 and its 200-day simple moving average is $9.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.88 earnings per share for the current year.

Analysts Set New Price Targets

FDMT has been the subject of several analyst reports. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday. Chardan Capital upgraded shares of 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $32.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.62.

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of FDMT. Jupiter Topco LLC bought a new position in 4D Molecular Therapeutics during the 2nd quarter worth approximately $76,466,000. BlackRock Inc. bought a new position in shares of 4D Molecular Therapeutics during the second quarter worth $60,463,000. Janus Henderson Group PLC grew its holdings in shares of 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after buying an additional 2,882,508 shares during the period. Trails Edge Capital Partners LP acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $29,631,296,000. Finally, State Street Corp increased its position in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after buying an additional 1,785,106 shares in the last quarter. 99.27% of the stock is owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.